Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Dual anti-HLH and antitumor efficacy of golidocitinib in relapsed/refractory PTCL-associated hemophagocytic lymphohistiocytosis: A retrospective safety and activity analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

BXBing XiangAZAilin ZhaoTNTing Niu

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows golidocitinib achieves response rates of 46.7% in peripheral T-cell lymphoma, indicating rapid anti-HLH benefits.

Key Points

  • Golidocitinib-based regimens achieved a rapid clinical improvement in hemophagocytic lymphohistiocytosis symptoms and biomarkers.
  • Outcomes included a 46.7% overall response rate and significant decreases in IL-6 and other inflammatory markers.
  • Treatment was evaluated in a retrospective cohort of sixteen patients with relapsed/refractory peripheral T-cell lymphoma.
  • These results support the potential of JAK1 inhibition for patients with aggressive lymphoma-associated HLH.

Cite This Study

Xiang et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d549https://doi.org/10.1182/blood-2025-6303
View Full Paper
Ask AI
Bookmark
Share